DK0563127T3 - Forbedret behandlingsfremgangsmåde til cancer - Google Patents

Forbedret behandlingsfremgangsmåde til cancer

Info

Publication number
DK0563127T3
DK0563127T3 DK92901177.3T DK92901177T DK0563127T3 DK 0563127 T3 DK0563127 T3 DK 0563127T3 DK 92901177 T DK92901177 T DK 92901177T DK 0563127 T3 DK0563127 T3 DK 0563127T3
Authority
DK
Denmark
Prior art keywords
chemotherapeutic agent
cancer cells
cancer
treatment
improved treatment
Prior art date
Application number
DK92901177.3T
Other languages
English (en)
Inventor
Lorne J Brandes
Original Assignee
Univ Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manitoba filed Critical Univ Manitoba
Application granted granted Critical
Publication of DK0563127T3 publication Critical patent/DK0563127T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK92901177.3T 1990-12-17 1991-12-16 Forbedret behandlingsfremgangsmåde til cancer DK0563127T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62786390A 1990-12-17 1990-12-17
US71197591A 1991-06-07 1991-06-07

Publications (1)

Publication Number Publication Date
DK0563127T3 true DK0563127T3 (da) 1994-11-28

Family

ID=27090549

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92901177.3T DK0563127T3 (da) 1990-12-17 1991-12-16 Forbedret behandlingsfremgangsmåde til cancer

Country Status (9)

Country Link
EP (1) EP0563127B1 (da)
JP (1) JP2706371B2 (da)
AT (1) ATE110966T1 (da)
AU (1) AU664978B2 (da)
CA (1) CA2098593C (da)
DE (1) DE69103908T2 (da)
DK (1) DK0563127T3 (da)
ES (1) ES2063574T3 (da)
WO (1) WO1992011035A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9303210D0 (en) * 1993-02-17 1993-03-31 Univ Manitoba Cancer treatment
AU749157B2 (en) * 1993-02-17 2002-06-20 University Of Manitoba Cancer treatment
US5432168A (en) * 1993-12-27 1995-07-11 University Of Manitoba Method of treatment of hormone-unresponsive metastatic prostate cancer
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
US6506876B1 (en) 1994-10-11 2003-01-14 G.D. Searle & Co. LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
US5863912A (en) * 1994-12-07 1999-01-26 Manitoba Cancer Treatment And Research Foundation Method of treatment of hormone-unresponsive metastiatic prostate cancer
JP2003530850A (ja) * 2000-04-14 2003-10-21 ユニバーシティー オブ サウス カロライナ リサーチ ファウンデーション 生物活性ヒスチジンアンモニアリアーゼのクローニング、過剰発現および治療用途
US6630454B2 (en) * 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
EP1441711A1 (en) * 2001-11-09 2004-08-04 The University of Manitoba Treatment of breast cancer
CA2497180A1 (en) * 2002-09-04 2004-03-18 The University Of Manitoba Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist
US11090275B2 (en) * 2015-10-27 2021-08-17 Jay Pharma Inc. Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1229604A (en) * 1984-02-14 1987-11-24 Lorne J. Brandes Aminoalkyl ethers of phenols as antiproliferative anticancer agents

Also Published As

Publication number Publication date
EP0563127B1 (en) 1994-09-07
CA2098593A1 (en) 1992-06-18
WO1992011035A1 (en) 1992-07-09
JP2706371B2 (ja) 1998-01-28
AU664978B2 (en) 1995-12-14
EP0563127A1 (en) 1993-10-06
ES2063574T3 (es) 1995-01-01
ATE110966T1 (de) 1994-09-15
AU9058391A (en) 1992-07-22
DE69103908T2 (de) 1995-01-05
JPH06505710A (ja) 1994-06-30
DE69103908D1 (de) 1994-10-13
CA2098593C (en) 1999-08-10

Similar Documents

Publication Publication Date Title
Ferreira et al. Prostaglandins and the mechanism of analgesis produced by aspirin-like drugs
ES2001950A6 (es) Procedimiento de obtencion de composiciones en emulsion para la administracion de farmacos hidrofobos ionizables escasamente hidrosolubles.
PT1033981E (pt) Formulacoes e metodos para reduzir a toxicidade de agentes antineoplasicos
ES2055911T3 (es) Compuesto farmaceutico adelgazante.
DK0563127T3 (da) Forbedret behandlingsfremgangsmåde til cancer
LV10183A (lv) Perorala kompozicija zarnu iekaisuma slimibu arstesanai
DE69836222D1 (de) Modifizierter tumor-nekrosefaktor
ATE231500T1 (de) Hydroxymatairesinol in der krebs-prevention
DK0725637T3 (da) Parenteralt busulfan til behandling af malign sygdom
NO20006604L (no) Fremgangsmåter og transdermale sammensetninger for lindring av smerte
JPS5735516A (en) Agent for increasing radiosensitivity or agent for increasing effect of substance having activity similar to radiation
TR200002969T2 (tr) Farmasötik bileşim.
SE8303003D0 (sv) Medel for att oka antitumorverkan hos antitumormedel
NL194959B (nl) Preparaat voor het toedienen van ijzer.
PT1102594E (pt) Utilizacao de cloreto de sodio para reduzir a toxicidade gastrointestinal de derivados de camptotecina
EA200300427A1 (ru) Противоопухолевая терапия, включающая производные дистамицина
DE3875611D1 (de) Pharmazeutische zusammensetzungen.
OA07029A (fr) Le chlorure de gallium, nouveau médicament anti-cancéreux.
DK1058544T3 (da) Inhibition af TNF-aktivitet med præparater, der omfatter heparin og oplöselige TNF-receptorer
DE10299023I1 (de) Antineoplastisch wirkender und den Antineoplastischen effekt Verstaerkender Wirkstoff
DE3163920D1 (en) Pharmaceutical preparations comprising polyprenyl compounds, especially as anti-cancer agents, and pharmaceutical compositions for the prevention and treatment of cancer and skin diseases
Li et al. Opiate effects on 5-fluorouracil disposition in mice
TR200000728T2 (tr) Kronik hepatit C&#39; nin tedavisinde IFN-alfa ve amantadin kullanımı.
Litvinov et al. Experimental estimation of isoniazid hepatotoxicity with bromsulphalein test.
IMAMURA et al. COMBINATION EFFECT OF-BIS (3-METHYLSULFONYLOXYPROPYL) AMINE AND 6-MERCAPTOPURINE ON AH-60C AND AH-109A